A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy

A Multi-Center, Randomized, Open Label Study To Evaluate Safety, Tolerability And Efficacy Of Treatment With Mitoxantrone; Pre-Treatment With Glatiramer Acetate (GA) Versus Treatment With GA Alone In Relapsing Forms Of Multiple Sclerosis.

CompletedPhase 2Relapsing MSNCT00203073

What it found

No results found

We found no results in the registry or in papers.

This trial finished 21 years ago. We found no results in the registry or in any paper that cites it.

What was tested

Treatment tested

What it measured

Main measures

  • Determine if short-term immunosuppression with mitoxantrone (Novantrone®) followed by chronic treatment with Glatiramer Acetate (GA) in comparison to treatment with GA for the same period of time but without immunosuppression is well-tolerated and safe

    15 months

Who could take part

Relapsing MS · 18 to 55 · EDSS 0.0 to 6.5

Show the full criteria

Inclusion criteria

1. Definite MS as determined by the McDonald criteria (Ann Neurol, July 2001) with a relapsing disease course. 2. 2.EDSS 0.0 - 6.5 inclusive 3. 18 to 55 years of age 4. 1 or more T1 Gadolinium-enhancing lesions but no more than 15 lesions 5. Able and willing to sign and date an informed consent form

Exclusion criteria

1. Patients ever treated with Glatiramer Acetate or Mitoxantrone. 2. Patients treated with interferons or IV immunoglobulins (IV Ig) in the previous 4 weeks prior to screening visits. 3. Patients treated with methotrexate or azathioprine in the previous 6 months prior to screening visits. 4. Patients ever treated with cyclophosphamide or Total Lymphoid Irradiation (TLI), or cladribine for injection or anthracenediones or anthracyclines, or prior mediastinal radiotherapy. 5. Patients treated with intravenous or oral steroids within 28 days prior to initial MRI. 6. Female patients must be non-pregnant, non-lactating, have a negative screening pregnancy test, and must use contraceptive methods deemed reliable by the investigator. 7. Male patients and their partners must use contraceptive methods deemed reliable by the investigator 8. LVEF \< 50% 9. Patients using catheters or Foley catheters 10. Patients who have any other known significant systemic medical disease which may confound the evaluation of the study results such as: ALS, cervical spondylitic myelopathy, syphilis, arteritis, cerebellar syndrome (i.e., due to heredodegeneration), B12/folate deficiency, lyme disease, HTLV 1-myelopathy 11. Patients with immune deficiency or other medical condition that would preclude treatment with Mitoxantrone or Glatiramer Acetate 12. Abnormal screening blood tests exceeding any of the limits defined below: Alanine transaminase (ALT) - twice the upper limit of normal Aspartate transaminase (AST) - twice the upper limit of normal Total white blood cell count \< 2.3 x 103/uL Baseline neutrophil counts of \< 1.5 x103/uL Platelet count \< 80 x 103/uL Creatinine >1.5 mg/dL Prothrombin time greater than 150% upper limit of normal 13. Patients with any medical or psychiatric conditions that would make the patient unsuitable for this research, as determined by the investigator.

As registered. Criteria can change, so ask the trial team or your neurologist.

About this trial

In the sponsor's words

It is thought that treating multiple sclerosis with Novantrone for a short period of time prior to treatment with Copaxone may enhance the onset effect of Copaxone.

Loading reviews and guidelines…

Related trials

History

    1. Started

      Jun 2003

    2. Main results due

      Jan 2005

    3. Finished

      Apr 2005

    Assembled by software from public sources.